GVR Report cover DNA Methylation Market Size, Share & Trends Report

DNA Methylation Market Size, Share & Trends Analysis Report By Technology (Bisulphite DNA Modification, Immunoprecipitation of Methylated DNA), By Application, By End-use, By Region, And Segment Forecasts, 2022 To 2030

  • Report ID: GVR453396
  • Number of Pages: 0
  • Format: Electronic (PDF)

DNA methylation is a process by which methyl groups are added to the target DNA molecule. The process results in the modification of gene expression and leads to the silencing of the required genes. The process is known to play a pivotal role in various cellular processes, such as cell differentiation, genomic imprinting, embryogenesis, and X-chromosome inactivation.

Moreover, the technology is an epigenetic form of gene regulation that is naturally critical to life processes, especially during gestational and postnatal developmental processes. It also primarily helps in the regulation and monitoring of the cell cycle along with cellular differentiation processes. Further, the process is also known to be featured in a definite pattern along with various disorders such as cancer, neurodegenerative disorders, and cardiovascular ailments.

The unprecedented rise in demand for epigenetics-based treatment strategies, along with extensive commercialization of nucleic acid-based diagnostic tests & kits is expected to accelerate the market growth. Moreover, the adaptive utility of next-generation sequencing (NGS) based techniques in drug development, gene therapy, and clinical research is also projected to drive the market during the forecast period.

Cancer progression is associated with genetic expressions and conditions. A recent research study on tissue-specific methylation suggests that DNA hypo-methylation helps enhance tumor transformation in a variety of pathways. Further, newer research has revealed that genomic 5-hydroxymethylcytosine is an intermediate in DNA de-methylation that results in cancer-related losses. Furthermore, decreased hydroxyl and DNA methylation both play important roles in carcinogenesis. There are many commercially available kits and panels to effectively identify specific sites that could give specific insights into the caused cancer condition. For instance, In May 2022, Twist Bioscience Corporation launched the Twist Human Methylome Panel, to aid applications in cancer metastasis, human development, and functional genetics. The panel facilitates the effective identification of a robust, collated set of genome-wide methylated cytosine, CpG sites and guanines, for the detection of biologically significant methylation signatures.

Moreover, the process also enables the detection of deoxyribonucleic acid fragments which are originated from tumor cells. The novel technology not only detects genomic alterations in the nucleic acid molecules released by tumor cells but also monitors the progression or response of a tumor to a therapeutic regime.

A gradual rise in the number of types of cancers, and numerous clinical trials conducted across the globe are projected to offer a favorable environment for market growth. There is also growing demand for kits-based DNA methylation due to its ease of use and superior outcomes. For instance, The Nucleo-pore DNA Methylation Kit facilitates a combination of DNA denaturation and bisulfite conversion in a single process. The uracils are essentially transformed into thymines, and the residues into cytosines using a PCR cycle.

DNA Methylation Market: Segmentation

Segments

Details

By Technology

  • Bisulphite DNA modification
  • Immunoprecipitation of methylated DNA
  • High resolution melt analysis
  • Other

By Application

  • DNA sequencing
  • Gene therapy
  • Diagnostic Immunoassay
  • Oncology
  • Research
  • Others

By End use

  • Hospital & Diagnostic laboratories
  • Pharmaceutical & Biotechnology companies
  • Research & Academia

By Product

  • Enzymes & reagents
  • Kits
  • Others

By Region

  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East & Africa

 

 

Major companies operating in the market include New England Biolabs, Sysmex Corporation, Abcam plc., F. Hoffmann-La Roche Ltd., Diagenode Diagnostics S.A., Thermo-Fisher Scientific Inc., Agilent Technologies Inc., BioRad Laboratories Inc., Exact Sciences Corporation, QIAGEN N.V., Active Motif, Inc., Illumina Inc., EpiGentek Group Inc., Pacific Biosciences Inc., New England Biolabs Inc., Merck KGaA, Zymo Research Corporation, F. Hoffmann-La Roche Ltd., PerkinElmer Inc.

gvr icn

GET A FREE SAMPLE

gvr icn

This FREE sample includes market data points, ranging from trend analyses to market estimates & forecasts. See for yourself.

gvr icn

NEED A CUSTOM REPORT?

We can customize every report - free of charge - including purchasing stand-alone sections or country-level reports, as well as offer affordable discounts for start-ups & universities.

Contact us now to get our best pricing.

esomar icon

ESOMAR certified & member

D&B icon

Leading SME award by D&B

We are GDPR and CCPA compliant! Your transaction & personal information is safe and secure. For more details, please read our privacy policy.